Riggins HeadshotPrincipal Investigator: Dr. Gregory Riggins

Research Institution: Johns Hopkins University 

Disease: Medulloblastoma, Glioblastoma

Research Description: Medulloblastoma is the most common malignant brain tumor in children, and brain cancers are the second leading cause of pediatric cancer-related deaths. Dr. Riggins’s recent studies have shown the antiparasitic drug mebendazole to be effective in animal models of aggressive brain tumors, including advanced gliomas and medulloblastomas. Because mebendazole has a history of safe use in patients, it has a relatively short pathway to new clinical trials. Dr. Riggins and his team have improved the formulation and anticancer performance of oral mebendazole, and this Phase I trial will examine dosage levels in recurrent pediatric brain cancers resistant to therapy. They hope to demonstrate not only safety, but to eventually provide the evidence and rationale for future Phase II studies.

CWR funding role: Participating funder

CWR Start date: 2016

Sign up for our eNewsletter today!


First Name

Cures Within Reach


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Tuesday the 20th. Copyright 2018 Cures Within Reach.